- Home
- ESRT vs AKRO Comparison
ESRT vs AKRO Comparison
Compare ESRT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- AKRO
- Stock Information
- Founded
- ESRT 2011
- AKRO 2017
- Country
- ESRT United States
- AKRO United States
- Employees
- ESRT N/A
- AKRO N/A
- Industry
- ESRT Real Estate Investment Trusts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ESRT Real Estate
- AKRO Health Care
- Exchange
- ESRT Nasdaq
- AKRO Nasdaq
- Market Cap
- ESRT 1.7B
- AKRO 1.8B
- IPO Year
- ESRT 2013
- AKRO 2019
- Fundamental
- Price
- ESRT $8.66
- AKRO $51.84
- Analyst Decision
- ESRT Hold
- AKRO Strong Buy
- Analyst Count
- ESRT 2
- AKRO 9
- Target Price
- ESRT $11.50
- AKRO $75.86
- AVG Volume (30 Days)
- ESRT 1.3M
- AKRO 2.2M
- Earning Date
- ESRT 02-19-2025
- AKRO 03-03-2025
- Dividend Yield
- ESRT 1.62%
- AKRO N/A
- EPS Growth
- ESRT N/A
- AKRO N/A
- EPS
- ESRT 0.28
- AKRO N/A
- Revenue
- ESRT $763,152,000.00
- AKRO N/A
- Revenue This Year
- ESRT N/A
- AKRO N/A
- Revenue Next Year
- ESRT $1.85
- AKRO N/A
- P/E Ratio
- ESRT $30.89
- AKRO N/A
- Revenue Growth
- ESRT 3.19
- AKRO N/A
- 52 Week Low
- ESRT $8.61
- AKRO $17.86
- 52 Week High
- ESRT $11.62
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ESRT 24.25
- AKRO 65.39
- Support Level
- ESRT $9.27
- AKRO $48.70
- Resistance Level
- ESRT $9.30
- AKRO $51.40
- Average True Range (ATR)
- ESRT 0.21
- AKRO 2.29
- MACD
- ESRT -0.05
- AKRO -0.90
- Stochastic Oscillator
- ESRT 4.37
- AKRO 35.50
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.